The following article features coverage from the American Urological Association (AUA) 2019 meeting. Click here to read more of Renal & Urology News’ conference coverage.

CHICAGO—Delaying nephrectomy for pT3 renal cell carcinoma (RCC) 10 weeks after diagnosis is associated with decreased 5-year overall survival, new study data presented at the 2019 American Urological Association annual meeting suggest.

Patients who underwent nephrectomy for pT3 RCC more than 10 weeks after diagnosis had a significant 24% increased 5-year mortality risk in adjusted analyses compared with those who underwent surgery within 10 weeks of diagnosis, Jiping Zeng, MD, a urology resident at Banner-University Medical Center in Tucson, and colleagues reported.

Using the National Cancer Database, Dr Zeng’s group identified 22,653 patients with a median follow-up duration of 31 months. The overall mortality rate at a 5-year follow-up was 42.9%. The median interval from diagnosis to nephrectomy was 30 days. Of the 22,653 patients, 3340 (14.7%) underwent nephrectomy more than 10 weeks after diagnosis.

On multivariable analysis, patients treated in academic or integrated network cancer centers, those without health insurance, and those with a median household income less than $38,000 were more likely to have a surgery delay greater than 10 weeks.

Read more of Renal & Urology News’ coverage of the AUA 2019 meeting by visiting the conference page.

Reference

Zeng J, Batai K, Lee B. Nephrectomy delay more than ten weeks from diagnosis is associated with decreased overall survival in pT3 RCC. Presented at the 2019 American Urological Association annual meeting held May 3-6 in Chicago. Abstract MP14-12.